Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy - PubMed
8 hours ago
- #Clinical Trial
- #Pediatric Health
- #Cardiology
- Mavacamten significantly reduced left ventricular outflow tract obstruction in adolescents with obstructive hypertrophic cardiomyopathy compared to placebo.
- The phase 3 trial involved 44 symptomatic adolescents, with results showing a mean gradient change of -48.5 mm Hg for mavacamten versus -0.5 mm Hg for placebo at week 28.
- Adverse events were similar between groups, with no deaths and no reductions in left ventricular ejection fraction below 50%.